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Abstract
Background and goal of study: there is evidence that periope-
rative intravenous ketamine and lidocaine reduce postoperati-
ve pain, postoperative opioids consumption, shortens hospital 
stay and accelerates intestinal function recovery. However, it 
has not been studied the beneficial effects in the intraopera-
tive period. The aim of this study was to evaluate the effect 
of a single dose of lidocaine and ketamine on intraoperative 
opioids requirements in patients undergoing elective gyneco-
logical laparotomies under general anesthesia. 
Materials and methods: we performed a single-centre, pros-
pective, randomized, double-blinded, placebo-controlled 
study. We included 33 patients (11 in the ketamine group, 11 
in the lidocaine group and 11 in the placebo group). Posto-
perative analgesia was accomplished by patient-controlled 
morphine. Patients were randomly assigned to receive either a 
1.5 mg/kg of 2% lidocaine, 0.5 mg/kg of 5% ketamine or 
0.9% saline bolus. The primary outcome was the opioids con-
sumption during surgery. The secondary outcomes included: 
emergence time, pain scores, opioids consumption within 24 h 
after surgery and side effects. 
Results: decreased intraoperative opioids requirements were 
noted in the experimental groups (ketamine: 402.3 ± 106.3 
Efecto de una dosis de lidocaína y ketamina sobre el 
consumo intraoperatorio de opioides en pacientes 
sometidas a cirugía ginecológica electiva bajo anestesia 
general. Estudio piloto aleatorizado y controlado con 
placebo.
Resumen
Introducción y objetivos del estudio: existe evidencia de que la 
administración perioperatoria de ketamina y lidocaína intravenosa 
reduce el dolor y el consumo de opioides postoperatorio, acorta 
la estancia hospitalaria y acelera la recuperación de la función in-
testinal. Sin embargo, no se han estudiado los efectos beneficio-
sos en el período intraoperatorio. El objetivo de este estudio fue 
evaluar el efecto de una única dosis de lidocaína y ketamina sobre 
el consumo intraoperatorio de opioides en pacientes sometidas a 
cirugía ginecológica electiva bajo anestesia general.
Material y métodos: estudio prospectivo, aleatorizado, doble 
ciego, controlado con placebo en un solo centro. Se incluyeron 
33 pacientes (11 en el grupo ketamina, 11 en el grupo lidocaí-
na y 11 en el grupo placebo). Para la analgesia postoperatoria 
se utilizó una bomba PCA (Analgesia Controlada por el Pacien-
te ) de morfina. Los pacientes fueron asignados al azar a uno 
de los tres grupos de estudio: 1,5 mg/kg de lidocaína al 2%, 
0,5 mg/kg de ketamina al 5% o solución salina 0.9%. La varia-
ble principal del estudio fue el consumo de opioides durante la 
cirugía. Las variables secundarias fueron: tiempo de educción 
de la anestesia, intensidad del dolor, consumo de opioides en 
las 24 horas posteriores a la cirugía y efectos adversos.
Resultados: se observó una disminución del consumo intraope-
ratorio de opioides en los grupos ketamina (402,3 ± 106,3) y 
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and lidocaine: 397.7 ± 107.5, compared with saline: 
561.4 ± 97.1); p = 0.001. We found a positive correlation be-
tween intraoperative opioids consumption and emergence 
time (r = 0.864, p < 0.001). There was no significant differen-
ce between the groups in VAS pain scores at rest within the 
first 24 postoperative hours. Total morphine consumption wi-
thin 24 h after surgery did not differ significantly among the 
groups (placebo: 27.54 ± 11.75; ketamine: 30.95 ± 7.88; lido-
caine 34.77 ± 10.25; p = 0.26). Postoperative nausea and vomi-
ting were more common in placebo group (it was observed in 
3 subjects in ketamine group, in 5 subjects in lidocaine group 
and in 9 subjects in placebo group; p = 0.027). 
Conclusion: our results do not support the use of intraoperati-
ve single dose of lidocaine or ketamine to reduce postoperative 
pain and postoperative opioids consumption after open gyne-
cological surgery. However, they seem to decrease intraopera-
tive opioids requirements and shorten emergence time. Never-
theless, these findings should be validating in further studies 
with large sample size.
KEY WORDS
Ketamine; Lidocaine; Analgesic agents; Perioperative period; 
Laparotomy
Farm Hosp. 2016;40(1):44-51
lidocaína (397,7 ± 107,5) frente al grupo placebo (561,4 ± 
97,1); p = 0,001. Se encontró una correlación positiva entre 
el consumo intraoperatorio de opioides y el tiempo de desper-
tar (r = 0,864, p <0,001). No hubo diferencias significativas 
respecto a la intensidad del dolor en reposo en las 24 horas 
posteriores a la cirugía. El consumo total de morfina en las 
primeras 24 horas tras la cirugía no difirió significativamente 
entre los grupos (placebo: 27,54 ± 11,75; ketamina: 30,95 ± 
7,88; lidocaína 34,77 ± 10,25; p = 0,26). Las náuseas y vómi-
tos postoperatorios fueron más frecuentes en el grupo placebo 
(se observó en 3 pacientes del grupo ketamina, en 5 del grupo 
lidocaína y en 9 del grupo placebo; p = 0,027).
Conclusión: Nuestros resultados no apoyan el uso de una única 
dosis intraoperatoria de lidocaína o ketamina para disminuir el 
dolor postoperatorio y el consumo de opioides tras cirugía gi-
necológica abierta. Sin embargo, si parece disminuir los reque-
rimientos intraoperatorios de opioides y acortar el tiempo de 
educción de la anestesia. No obstante, estos resultados deben 
ser validados en futuros estudios con mayor tamaño muestral.
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Introduction
Opioids are widely used in the perioperative period 
because of their profound analgesic effect. However, 
this drug can be associated with undesirable side effects, 
which may include respiratory depression, hypotension, 
sedation, nausea and vomiting, urinary retention and 
postoperative ileus1-3. Side effects related with analge-
sia in surgical patients can be problematic and can lead 
to increased institutional costs, longer hospital length of 
stay, and an overall increase in patient dissatisfaction4-6.
Given the multiplicity of mechanisms involved in pain 
pathophysiology, an appropriate approach would be a 
multimodal analgesia regimen that uses a combination 
of opioids and multiple agents aiming at augmenting 
their reciprocal effects7-9.
One medication that has shown promise in providing 
analgesia effect is lidocaine. This is an amide local anes-
thetic agent that works by blocking sodium channels in 
the neural cascade. Recent investigations suggest that 
intravenous lidocaine may be beneficial in biochemical 
pain processes4,6,10-12. 
Although the exact mechanism and analgesic-sparing 
effect of parenterally administered lidocaine is unclear, 
some authors speculate that it acts more as an antihype-
ralgesic than as a direct analgesic. Is known central sen-
sitization to be induced by the mechanosensitive noci-
ceptor class of receptors. These nociceptors are known 
to be sensitive to small-dose lidocaine10.
Moreover, important mechanisms in the genesis of 
pain include N-methyl-D-aspartate receptor (NMDAR) 
activation and up-regulation and inflammatory respon-
ses in the spinal cord13-15. In this regard, ketamine, a 
non-competitive antagonist of the N-methyl-D-asparta-
te (NMDA) receptor, has received increased interest in 
recent years as an analgesic for acute pain management. 
At relatively high dose, ketamine produces anesthesia, 
whereas at sub-anesthetic dose, it is a potent analgesic. 
Low doses of ketamine have been proposed to prevent 
opioid tolerance and opioid-induced-hyperalgesia16,17.
The effect of ketamine on perioperative inflammatory 
responses has been studied in patients undergoing total 
hip arthroplasty, hysterectomy, thoracotomy, cardiac and 
spine surgery18-22. 
Thus, these agents could have an important analgesic 
effect not only in the postoperative period, but also in 
the intraoperative period. Therefore, the main objective 
of this study was to evaluate the effect of a single dose 
of lidocaine and ketamine on intraoperative opioids re-
quirements in patients undergoing elective gynecologi-
cal laparotomies under general anesthesia.
Materials and Methods
This was a single-centre, prospective, randomized, 
double-blinded, placebo-controlled design. The patients 
were recruited for participation in the study after appro-
val of the protocol by the local medical ethics committee 
of Nuestra Señora de Valme University Hospital, Seville, 
Spain. Informed written consent was obtained from all 
participants according to the Declaration of Helsinki. 
Thirty-three female, aged 18-55 years, undergoing 
elective open gynecological surgery under general anes-
thesia were enrolled in the study. 
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Exclusion criteria were: age <18 years or >55 years, 
preexisting chronic pain requiring treatment, contrain-
dication to ketamine or lidocaine, oncologic surgery, 
history of significant neurological or psychiatric disease 
(e.g., increased cranial pressure, seizure disorder requi-
ring medication within the previous 2 years, psychosis), 
substantial hepatic (alanine aminotransferase or aspar-
tate aminotransferase >2 times normal) or renal impair-
ment (serum creatinine >2 mg/dL) and previous substan-
ce abuse. 
The primary outcome was the opioids consumption 
during surgery. The secondary outcomes were the emer-
gence time, pain scores, opioids consumption within 24 
h after surgery and side effects.
Patients were randomly assigned, using computer-ge-
nerated random numbers and concealed opaque enve-
lopes to receive either, a 1.5 mg/kg of 2% lidocaine, 0,5 
mg/kg of 5% ketamine or 0.9% saline bolus. 
The day of surgery, coded 10-mL syringes of lidocai-
ne, ketamine, or saline were prepared by the nurse in 
the Post-Anesthesia Care Unit (PACU). Each syringe was 
indistinguishable from the other, and only the nurse who 
prepared the syringes was aware of their actual compo-
sition. The anesthesiologist in charge, the surgeon, the 
nursing staff and the patients were blind to the group 
assignment until the conclusion of the study.
Every patient was admitted one day before surgery 
according to institutional standards. In the operating 
room, intravenous access was secured, and routine mo-
nitoring was established using an electrocardiogram, 
non-invasive blood pressure, heart rate, oxygen satura-
tion and end-tidal carbon dioxide (Et CO2) (Datex-Ohme-
da S/5 Compact Critical Care Monitor; GE Healthcare). 
All patients were preoxygenated with 100% oxygen via 
facemask for 3 to 5 minutes before induction of anes-
thesia. Anesthesia was induced with an intravenous 
administration of 1-2 mg of midazolam, 2 μg/kg of 
0.005% fentanyl and 2 mg/kg of 1% propofol. Orotra-
cheal intubation was facilitated with 0,6 mg/kg of 1% 
rocuronium and respiratory frequency and tidal volume 
were adjusted to maintain the Et CO2 between 32 to 35 
mmHg. Dexamethasone 4 mg i.v could be administered 
during induction of anesthesia in all patients with mode-
rate or high risk of postoperative nausea and vomiting 
(PONV), according Apfel’s model23,24. 
Maintenance of anesthesia was accomplished using 
propofol according to the Bispectral Index (BIS) and ad-
ditional fentanyl was administered as needed during 
anesthesia with a 20% increase in blood pressure or if 
the heart rate was greater than 100 beats/min. The to-
tal amount of fentanyl used were recorded at the end 
of the procedure. Rocuronium boluses were given for 
intraoperative muscle relaxation to maintain a moderate 
neuromuscular block to train-of-four stimulation (TOF). 
The anesthetist administered lidocaine, ketamine, or 
saline bolus 5 minutes before the surgical incision.
Aproximately 15 to 30 minutes before skin closure 4 
mg of 0,2% ondansetron, 2g of 40% metamizol and 
50 mg of 2,5% dexketoprofen were administered in all 
groups. Neuromuscular blockade was antagonized using 
IV neostigmine, 0.05 mg/kg, and atropine 0.015 mg/kg 
after the reappearance of T4 in the TOF.
Emergence time from anesthesia was collected (me-
asured in minutes from discontinuation of propofol in-
fusions to the moment at which the patient awoke and 
endotracheal tube was removed).
After removal of the endotracheal tube, subjects were 
transported to the PACU. Total surgical time (measured 
in minutes from surgical incision to skin closure) was re-
corded.
On admission to the PACU, a postoperative pain was 
assessed as soon as the subject was alert and able to 
answer questions. A level of abdominal pain was as-
sessed using a 0 to 10 Verbal Analogue Scale (VAS), in 
which a rating of “0” indicated “absence of pain” and 
a score of “10” indicated the “worst pain imaginable”. 
VAS also was recorded at 2, 4, 8 and 24 h postoperati-
vely. 
At the same time points, sedation (was scored as 1 = 
alert, 2 = asleep, alert after arousal, 3 = asleep, drowsy 
after arousal, 4 = asleep, difficult to rouse, and 5 = una-
rousable), hallucinations, pruritus, incidence of any nau-
sea or vomiting, ileus, respiratory depression and any 
signs and symptoms of unexpected or major side effects 
were assessed. Research personnel, blind to the alloca-
tion, recorded these variables.
The amount of intraoperative opioid use was recor-
ded. Patients were connected to morphine-PCA and 
morphine was given intravenously during the first 24 h 
in boluses of 1,5 mg using Patient Controlled Analgesia 
(PCA), with a minimum interval of 10 min between two 
doses. No other analgesics were used. The analgesic re-
quirements for the first 24 hours were recorded.
Statistical Analysis
The distribution of data was determined using the 
Kolmogorov-Smirnov analysis. 
Data were expressed as mean (standard deviations), 
and nonparametric data as median (interquartile ran-
ge). Categorical data were compared among groups 
using chi-square test and Fisher exact test. Parametric 
data were compared using an unpaired student’s t-test, 
and nonparametric data using a Mann-Whitney test. To 
compare numerical variables between more than two 
groups ANOVA was conducted. Data that were not nor-
mally distributed were compared among groups using a 
Kruskal-Wallis test. The relationship between numerical 
variables was calculated using the Pearson correlation 
coefficient. A P value of <0.05 was considered statisti-
cally significant. All statistical analyses were conducted 
using software from the Statistical Package for the Social 
Sciences (SPSS, Version 18.0, Chicago, IL, USA). 
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Results 
Thirty-three patients were analyzed (11 in the ketami-
ne group, 11 in the lidocaine group and 11 in the place-
bo group). All subjects completed the protocol without 
unexpected or major side effects. Patient flow throu-
ghout the study, according to the CONSORT statement, 
is shown in figure 1.
There were no differences in age, weight, height, 
body mass index or duration of surgery between treat-
ment groups (Table 1). 
Decreased intraoperative fentanyl requirements were 
noted in the experimental groups compared with the 
control group (Figure 2). However, the ketamine group 
and lidocaine group did not differ significantly among 
them (p = 1.00). 
The emergency time was significantly longer in the 
placebo group (11.64 ± 2.11) compared to ketamine 
group (8.91 ± 2.21, p = 0.004) and to the group that re-
ceived lidocaine (7.91 ± 1.37, p < 0.001). However, there 
were no significant differences in emergency time be-
tween ketamine and lidocaine groups (p = 0.270) (Fi-
gure 3). As shown in figure 4, we found a positive co-
rrelation between intraoperative fentanyl consumption 
and emergence time (r = 0.864, p < 0.001). The highest 
intraoperative fentanyl requirements observed in the 
placebo group compared to other groups, was probably 
a condition that may have contributed to an increase in 
emergency time in this group. 
Morphine PCA was used for 24 h by 11 patients in 
each group. Table 2 shows the morphine consumption 
for groups during the first 24 postoperative hours. The 
mean ± SD total morphine consumption did not differ sig-
nificantly among groups (placebo groups 27.54 ± 11.75, 
ketamine group 30.95 ± 7.88 and lidocaine group 
34.77 ± 10.25; p = 0.260). There was no difference be-
tween the groups in VAS pain scores at rest from 0 to 24 
hours postoperatively. A trend toward lower VAS scores 
was noted at 24 hours after surgery in all groups (Table 2). 
No patients complained of hallucinations, dysphoria 
or disorientation. Sedation scores were similar among 
groups, and no patient had a score more than 2. Sta-
tistically significant difference in the incidence of PONV 
was found between groups. PONV was observed in 3 
Enrolment
Assessed for eligibility (n=39)
Randomised (n=33)
Allocation
Excluded (n=6)
Not meeting inclusion criteria (n=0)
Declined to participate (n=6)
Other reasons (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Analysed (n=11)
Excluded from analysis (n=0)
Analysed (n=11)
Excluded from analysis (n=0)
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Follow-up
Lost to follow-up (n=0)
Discontinued intervention (n=0)
Analysis
Analysed (n=11)
Excluded from analysis (n=0)
Lidocaine group (n=11)
Allocated to intervention (n=11)
Received allocated intervention (n=11)
Did not receive allocated intervention (n=0)
Ketamine group (n=11)
Allocated to intervention (n=11)
Received allocated intervention (n=11)
Did not receive allocated intervention (n=0)
Placebo group (n=11)
Allocated to intervention (n=11)
Received allocated intervention (n=11)
Did not receive allocated intervention (n=0)
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) flow chart.
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subjects in ketamine group, in 5 subjects in lidocaine 
group and in 9 subjects in placebo group (p = 0.027). 
Regarding itching, there was no significant difference 
among groups (p > 0.05). No other adverse events were 
observed in the postoperative period. There were no sur-
gical complications.
Discussion
This study shows 2 main findings. First, a small in-
travenous single dose of lidocaine and ketamine given 
before skin incision reduces intraoperative opioids re-
quirements in patients undergoing gynecological lapa-
rotomies under general anesthesia. Second, the subjects 
in the lidocaine and ketamine groups had substantially 
Table 1. Patients’ characteristics and operative details
ASA physical status
I
II
III
n (%)
10 (30.3)
21 (63.6)
2 (6.1)
Placebo
(n=11)
Lidocaine 
(n=11)
Ketamine 
(n=11)
P value
Age (yr) 45.2 ± 4.2 46.4 ± 6.2 43.1 ± 7.2 0.43
Weight (kg) 73.1 ± 12.1 68.3 ± 6.8 65.3 ± 14.9 0.30
Height (cm) 160 ± 0.1 161 ± 0.1 160 ± 0.1 0.88
BMI (kg/m2) 28.4 ± 4.4 25.6 ± 2.4 25.3 ± 5.0 0.17
Placebo
(n=11)
Lidocaine 
(n=11)
Ketamine 
(n=11)
P value
Duration of surgery (min) 91.4 ± 20.1 82.8 ± 14.0 88.2 ± 17.4 0.51
Data are presented as numbers (%) and mean (±SD). ASA, American Society of Anaesthesiologists. BMI, Body Mass Index. 
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Figure 2. Intraoperative opioids consumption.
IOP: Intraoperative. In ketamine group: 402.3 ± 106.3. In lido-
caine group: 397.7 ± 107.5. In placebo group: 561.4 ± 97.1
Figure 3. The anesthetic emergence time in study groups.
The emergency time was significantly longer in the placebo 
group (11.64 ± 2.11) compared to ketamine group (8.91 ± 2.21, 
p = 0.004) and to the group that received lidocaine (7.91 ± 1.37, 
p < 0.001).
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Figure 4. Emergence time according to intraoperative fentanyl 
consumption.
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shorter emergence time than the placebo group. These 
findings are particularly important in the ambulatory sur-
gery population because these patients do not have the 
structured support of a hospital staff and are, therefore, 
expected to have a faster recovery. 
In our study, no intravenous infusion of lidocaine 
and ketamine was use, an aspect that differentiates this 
study from most previous researches. The lack of signifi-
cant differences between the groups in VAS pain scores 
and opioids consumption from 0 to 24 hours postopera-
tively may be influenced by this fact. 
Lidocaine regimens vary amongst the studies inclu-
ded in our study. Most of the studies have reported 
lower pain scores and decreased postoperative opioids 
requirement used intravenous infusion of lidocaine af-
ter bolus dosing25-30. The half-life of lidocaine has been 
reported to be about 100 minutes following bolus in-
jection or infusions lasting less than 12 hours, showing 
more linear pharmacokinetics31. Therefore, after a single 
dose of lidocaine the dip in concentrations to below the 
therapeutic range occurs 1-3 hours after its administra-
tion32. 
When systemic lidocaine is administered in the ope-
rative period, it likely prevents the induction of central 
hyperalgesia10. Grigoras A et al.33, who observed a de-
crease the incidence of persistent pain after breast sur-
gery, highlight this fact.
Systematic review of multiple studies documented a 
reduction in perioperative pain when IV lidocaine infu-
sions supplement general anesthetics4. However, there 
are also exceptions, Wuethrich PY et al.34 found that sys-
temic perioperative lidocaine administration over 24 h 
did not influence opioid consumption after laparoscopic 
renal surgery.
The acute analgesic effects of ketamine are generally 
believed to be mediated through the blockade of phen-
cyclidine binding site of N-methyl-d- aspartate (NMDA) 
receptors of the nociceptive neurons. In addition, va-
rious studies, including clinical and preclinical research, 
have shown that ketamine has an anti-inflammatory 
effect35,36. However, is currently unclear if the anti-in-
flammatory effect it is mediated by NMDA or non-NM-
DA mechanisms. 
One review concluded that a single bolus dose of ke-
tamine decreased IV and epidural opioids requirements 
in seven of 11 studies37. A more recent Cochrane review 
analyzed 37 studies (2240 patients) and found that su-
banesthetic ketamine doses were effective in reducing 
24 h morphine requirements and the incidence of PONV; 
the adverse effects were mild or absent38. Our results 
showed a lower incidence of PONV in the ketamine 
group, but there was no difference in opioid consump-
tion at 24 hours postoperatively. 
Ketamine combined with opioids potentiates analge-
sia, thus reducing the need for large opioids doses39,40. It 
has been estimated that pain is reduced by 20-45%39,41,42. 
Nesher N et al.42 have demonstrated that even smaller IV 
doses (≤ 250 mcg/kg) effectively controlled opioid-resis-
tant pain, although it was associated with a brief period 
of sedation (< 2 min) immediately after the IV injection, 
but with no psychomimetic events.
The data of ketamine use available in the literature 
has led to conclude that it can reduce postoperative pain 
intensity, based on Level A evidence. The incidence of its 
benefit in reducing postoperative nausea and vomiting 
(PONV) has been confirmed by Level B evidence, and the 
effect on lowering the required dose of morphine by 30-
50% by Level A evidence43. Regarding adverse events, 
ketamine increased the incidence of neuropsychiatric 
effects (eg, hallucinations) and decreased the incidence 
of postoperative nausea and vomiting, but did not alter 
the incidence of sedation or other side effects16.
The limitations of this study include reliance on the 
accuracy of patient self-reported data and reliance on a 
convenience sample recruited from 1 centre, which may 
limit the generalisability of the results. Our study was 
restricted to women by nature of the surgery. Regarding 
adverse events, we consider a larger sample of patients 
would be needed to draw conclusions. Finally, although 
the monitoring of neuromuscular blockade was perfor-
med in all patients, the train-of-four was not collected, a 
point to be considered in future studies.
Table 2. Morphine consumption at 24 hours and postoperative VAS scores
Placebo
(n=11)
Ketamine
(n=11)
Lidocaine
(n=11)
P value
24 h Morphine consumption 27.54 ± 11.75 30.95 ± 7.88 34.77 ± 10.25 0.260
VAS scores
On admission to the PACU 6 (5-6) 5 (5-6) 5 (5-7) 0.332
2 hours 5 (3-6) 5 (4-5) 5 (4-5) 0.664
4 hours 4 (3-4) 4 (3-4) 5 (4-5) 0.125
8 hours 3 (3-4) 4 (4-4) 3 (3-4) 0.776
24 hours 2 (1-3) 2 (1-3) 2 (1-3) 0.846
Data are reported as mean (±SD) and median (IR). VAS, Visual Analogue Scale. PACU, Post-Anesthesia Care Unit.
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In summary, our results do not support the use of in-
traoperative single dose of lidocaine or ketamine to re-
duce postoperative pain and postoperative opioids con-
sumption after open gynecological surgery. However, 
they seem to decrease intraoperative opioids require-
ments and shorten emergence time, particularly impor-
tant in the ambulatory surgery population. Nevertheless, 
these findings should be validating in further studies 
with large sample size.
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